| Code | CSB-RA025141MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Tavo-101, targeting thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that plays a critical role in initiating and sustaining type 2 inflammatory responses. TSLP is released by damaged epithelial cells in response to allergens, pathogens, and environmental irritants, activating dendritic cells and promoting Th2 cell differentiation. Elevated TSLP expression has been implicated in the pathogenesis of allergic diseases including asthma, atopic dermatitis, chronic rhinosinusitis, and eosinophilic esophagitis, making it an important therapeutic target for type 2 inflammatory conditions.
Tavo-101 represents an investigational anti-TSLP antibody designed to neutralize TSLP activity and interrupt downstream inflammatory cascades. This biosimilar provides researchers with a valuable tool for investigating TSLP-mediated immune mechanisms, exploring epithelial-immune cell interactions, and studying the role of type 2 inflammation in allergic and respiratory diseases. The antibody supports various in vitro and in vivo research applications aimed at understanding TSLP biology and evaluating potential therapeutic interventions.
There are currently no reviews for this product.